- Home
- UP vs AKBA Comparison
UP vs AKBA Comparison
Compare UP & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UP
- AKBA
- Stock Information
- Founded
- UP 2013
- AKBA 2007
- Country
- UP United States
- AKBA United States
- Employees
- UP N/A
- AKBA N/A
- Industry
- UP Aerospace
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- UP Consumer Discretionary
- AKBA Health Care
- Exchange
- UP Nasdaq
- AKBA Nasdaq
- Market Cap
- UP 1.2B
- AKBA 958.6M
- IPO Year
- UP N/A
- AKBA 2014
- Fundamental
- Price
- UP $1.47
- AKBA $3.85
- Analyst Decision
- UP
- AKBA Strong Buy
- Analyst Count
- UP 0
- AKBA 5
- Target Price
- UP N/A
- AKBA $6.90
- AVG Volume (30 Days)
- UP 2.0M
- AKBA 3.9M
- Earning Date
- UP 08-07-2025
- AKBA 08-07-2025
- Dividend Yield
- UP N/A
- AKBA N/A
- EPS Growth
- UP N/A
- AKBA N/A
- EPS
- UP N/A
- AKBA N/A
- Revenue
- UP $772,533,000.00
- AKBA $184,909,000.00
- Revenue This Year
- UP $174.46
- AKBA $26.88
- Revenue Next Year
- UP N/A
- AKBA $44.34
- P/E Ratio
- UP N/A
- AKBA N/A
- Revenue Growth
- UP N/A
- AKBA N/A
- 52 Week Low
- UP $0.74
- AKBA $1.07
- 52 Week High
- UP $4.00
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- UP 55.16
- AKBA 62.44
- Support Level
- UP $1.34
- AKBA $3.81
- Resistance Level
- UP $1.55
- AKBA $4.08
- Average True Range (ATR)
- UP 0.14
- AKBA 0.15
- MACD
- UP 0.03
- AKBA -0.02
- Stochastic Oscillator
- UP 72.44
- AKBA 68.45
About UP Wheels Up Experience Inc.
Wheels Up Experience Inc is a provider of on-demand private aviation in the United States. It is pioneering data and technology-driven solutions that connect consumers to safety-vetted and verified private aircraft. It connects private flyers to aircraft, and one another, through an open platform that enables life's most important experiences. Its offering is delivered through a mix of programmatic and charter options that strategically utilize its owned and leased aircraft fleet and an "asset-light" charter model to deliver a greater range of global travel alternatives. The company operates in a single operating and reportable segment, private aviation services. Geographically the company generates the majority of its revenue from the United States.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.